These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 30745819)

  • 41. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.
    Cui Y; Wang Q; Chang R; Zhou X; Xu C
    J Agric Food Chem; 2019 Mar; 67(10):2754-2762. PubMed ID: 30798598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism.
    Zhou Y; Ding YL; Zhang JL; Zhang P; Wang JQ; Li ZH
    Biomed Pharmacother; 2018 Jan; 97():1397-1408. PubMed ID: 29156529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease.
    Leung TM; Nieto N
    J Hepatol; 2013 Feb; 58(2):395-8. PubMed ID: 22940046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
    Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
    World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
    Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
    Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD).
    Ajaz S; McPhail MJ; Gnudi L; Trovato FM; Mujib S; Napoli S; Carey I; Agarwal K
    Mitochondrion; 2021 Mar; 57():119-130. PubMed ID: 33387664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
    Liu J; Wang G; Jia Y; Xu Y
    Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding nutritional interventions and physical exercise in non-alcoholic fatty liver disease.
    Ordonez R; Carbajo-Pescador S; Mauriz JL; Gonzalez-Gallego J
    Curr Mol Med; 2015; 15(1):3-26. PubMed ID: 25601465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
    Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
    World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.
    Alamri H; Patterson NH; Yang E; Zoroquiain P; Lazaris A; Chaurand P; Metrakos P
    Anal Bioanal Chem; 2019 Feb; 411(4):885-894. PubMed ID: 30515538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inflammation is not the cause of an elevated serum ferritin in non-alcoholic fatty liver disease.
    Beaton MD; Chakrabarti S; Adams PC
    Ann Hepatol; 2014; 13(3):353-6. PubMed ID: 24756010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model.
    Müller P; Messmer M; Bayer M; Pfeilschifter JM; Hintermann E; Christen U
    J Autoimmun; 2016 May; 69():51-8. PubMed ID: 26924542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Non-alcoholic fatty liver disease (NAFLD) /non-alcoholic steatohepatitis (NASH) and nutrition].
    Ishii KA; Takamura T
    Clin Calcium; 2016 Mar; 26(3):363-7. PubMed ID: 26923972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?
    Gao B; Tsukamoto H
    Gastroenterology; 2016 Jun; 150(8):1704-9. PubMed ID: 26826669
    [No Abstract]   [Full Text] [Related]  

  • 59. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
    Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
    World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).
    Podrini C; Borghesan M; Greco A; Pazienza V; Mazzoccoli G; Vinciguerra M
    Curr Pharm Des; 2013; 19(15):2737-46. PubMed ID: 23092327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.